Could a common arthritis drug tame Sjogren's syndrome?
NCT ID NCT04496960
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This early-phase trial tested the safety of tofacitinib (Xeljanz), an oral drug used for rheumatoid arthritis, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants took the drug or a placebo daily for 168 days. Researchers monitored side effects and disease activity to see if the drug is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib (Xeljanz)
What this could lead to
If successful, this could point toward a new oral treatment option to control Sjogren's syndrome symptoms and reduce disease activity.
What could go wrong
This is an early-phase safety trial with only 23 participants, so results may not apply to everyone. Tofacitinib can have side effects like infections and blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.